Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease
(PTLD) is an important cause of morbidity and mortality following transpla
ntation, and it occurs more frequently in children than in adults. Of 22 (5
%) children at our institution who developed tissue-proven PTLD 1-60 months
(mean 16.5 months) following organ transplant, 11 died: nine of these 22 p
atients developed PTLD between 1989 and 1993, and seven (78%) died: the rem
aining 13 developed PTLD between 1994 and 1998, and four (31%) died (p = 0.
08). All nine patients who developed PTLD <6 months after transplant died,
but II of 13 patients who manifested disease <greater than or equal to> 6 m
onths after transplant survived (p = 0.0002), Ten of 11 (91%) survivors. bu
t only two of eight (25%) children who died, had serologic evidence of EBV
infection at the time of PTLD diagnosis (p=0.04), EBV seroconversion identi
fied patients at risk for developing PTLD, but also characterized patients
with sufficient immune function to survive EBV-related lymphoid proliferati
on. In situ hybridization for EBER1 mRNA was diagnostically helpful because
it detected EBV in tissue sections of all 20 patients with B-cell PTLD, in
cluding: those with negative serology.